Redx Pharma, the drug discovery and development company focused on cancer and fibrosis, has appointed Sarah Gordon Wild as an Independent non-Executive Director, with effect from 1 July 2020.
Gordon brings extensive investment experience in the biotechnology sector to her role at Redx. She currently also serves as a Non-Executive Director of Oxford Nanopore Technologies and Evox Therapeutics, as well as being a Board Member of Lone Pine Capital's Offshore Funds.
Between 1998-2003 Sarah was Managing Director, Management Committee Member and Senior Healthcare Analyst at Lone Pine Capital. Before this, for over 15 years, Sarah was a senior biotechnology/healthcare analyst on Wall Street at firms including; Amerindo Investments Advisors, Hambrecht & Quist, Kleinwort Grieveson, and Greig Middleton.
Gordon graduated from Aberdeen University with a BSc (Hons) in Zoology and with an MSc from Imperial College, London in Social & Economic Aspects of Science and Technology in Industry.
Iain Ross, Chairman of the Board of Redx said: "We are delighted to welcome Sarah to the Board. I am confident that Redx will benefit from her counsel and deep understanding of the biotechnology sector and capital markets as we seek to build a leading biotech company focused on novel medicines that have the potential to transform the treatment of oncology and fibrosis."
Sarah Gordon Wild added: "I am excited to be joining the Board as a non-executive director. Over a relatively short space of time, Redx has established a strong track record as a medicinal chemistry team and now has focused on a few very exciting programmes, as well as a strong management team. I look forward to seeing this pipeline progress in my Board role."